298 related articles for article (PubMed ID: 31923345)
1. A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis.
Gonçalves CS; Xavier-Magalhães A; Martins EP; Pinto AA; Pires MM; Pinheiro C; Reis RM; Sousa N; Costa BM
Mol Oncol; 2020 Jun; 14(6):1224-1241. PubMed ID: 31923345
[TBL] [Abstract][Full Text] [Related]
2.
Gonçalves CS; Vieira de Castro J; Pojo M; Martins EP; Queirós S; Chautard E; Taipa R; Pires MM; Pinto AA; Pardal F; Custódia C; Faria CC; Clara C; Reis RM; Sousa N; Costa BM
Theranostics; 2018; 8(17):4805-4823. PubMed ID: 30279739
[TBL] [Abstract][Full Text] [Related]
3. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
5. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
6. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.
Costa BM; Smith JS; Chen Y; Chen J; Phillips HS; Aldape KD; Zardo G; Nigro J; James CD; Fridlyand J; Reis RM; Costello JF
Cancer Res; 2010 Jan; 70(2):453-62. PubMed ID: 20068170
[TBL] [Abstract][Full Text] [Related]
7. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
[TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
10. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
11. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
13. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
14. Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.
Martins EP; Gonçalves CS; Pojo M; Carvalho R; Ribeiro AS; Miranda-Gonçalves V; Taipa R; Pardal F; Pinto AA; Custódia C; Faria CC; Baltazar F; Sousa N; Paredes J; Costa BM
Mol Oncol; 2022 Jul; 16(14):2611-2631. PubMed ID: 34919784
[TBL] [Abstract][Full Text] [Related]
15. The long non-coding RNA
Xavier-Magalhães A; Gonçalves CS; Fogli A; Lourenço T; Pojo M; Pereira B; Rocha M; Lopes MC; Crespo I; Rebelo O; Tão H; Lima J; Moreira R; Pinto AA; Jones C; Reis RM; Costello JF; Arnaud P; Sousa N; Costa BM
Oncotarget; 2018 Mar; 9(21):15740-15756. PubMed ID: 29644006
[TBL] [Abstract][Full Text] [Related]
16. Wnt-Induced Stabilization of KDM4C Is Required for Wnt/β-Catenin Target Gene Expression and Glioblastoma Tumorigenesis.
Chen Y; Fang R; Yue C; Chang G; Li P; Guo Q; Wang J; Zhou A; Zhang S; Fuller GN; Shi X; Huang S
Cancer Res; 2020 Mar; 80(5):1049-1063. PubMed ID: 31888886
[TBL] [Abstract][Full Text] [Related]
17. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
[TBL] [Abstract][Full Text] [Related]
18. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
19. DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival.
Weng JY; Salazar N
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498463
[TBL] [Abstract][Full Text] [Related]
20. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]